Link to page: Collaborative Research Center on the Wnt signaling pathway enters second funding period
Funding

Collaborative Research Center on the Wnt signaling pathway enters second funding period

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding the Collaborative Research Center "Mechanisms and Functions of the Wnt Signaling Pathway" (SFB 1324), founded in 2017, for another four years with approximately 11.5 million euros. The SFB researchers are investigating the network of Wnt signaling proteins, the misregulation of which can result in serious diseases such as cancer.

Link to page: High-resolution molecular map of endothelial cells identifies new mechanisms of liver regeneration
Latest News

High-resolution molecular map of endothelial cells identifies new mechanisms of liver regeneration

Blood vessels control the function of organs. Vessel-lining endothelial cells perform important control and safeguarding functions. Yet, the underlying molecular mechanisms are hitherto poorly understood. Scientists at the German Cancer Research Center (DKFZ) and at the European Center for Angioscience (ECAS) at Heidelberg University have now succeeded for the first time in generating a high-resolution, multidimensional map of gene and protein expression of endothelial cells in the liver. This allows precise insights into the mechanistic understanding of liver function and the control of liver regeneration.

Link to page: How "paralyzed" immune cells can be reactivated against brain tumors
Latest News

How "paralyzed" immune cells can be reactivated against brain tumors

Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor. These results confirm that therapeutic vaccines or immunotherapies are more effective against brain tumors if active substances are simultaneously used to promote the suppressed immune system.

We are asking for your support

Your Donation for Cancer Research
Link to page: Immune cells promote proinflammatory fatty liver disease
Latest News

Immune cells promote proinflammatory fatty liver disease

A particular type of dendritic cell is responsible for the tissue damage that occurs in non-alcoholic steatohepatits (NASH) in mice and humans. The dendritic cells cause aggressive, proinflammatory behavior in T cells, as now discovered by researchers from the German Cancer Research Center (DKFZ) in collaboration with colleagues from Israeli research institutes. Blocking these dendritic cells alleviates symptoms in mice. This type of approach might also prevent the development of serious liver damage in NASH patients.

Link to page: Apply now for a Postdoctoral Fellowship at the DKFZ!
Deadline 15 September 2021

Apply now for a Postdoctoral Fellowship at the DKFZ!

Are you looking for an excellent research environment to make your next step? Apply now!

Information


Search for research topic

Link to page: Mahak Singhal awarded the Helmholtz Doctoral Prize 2020
Award

Mahak Singhal awarded the Helmholtz Doctoral Prize 2020

How do tumor cells manage to spread through the body via the blood and lymph vessels? Mahak Singhal made outstanding discoveries on this topic in his doctoral thesis at the German Cancer Research Center. The aim of his work was to identify new ways of reducing tumor metastasis. In recognition of this excellent achievement, the Helmholtz Association has awarded him the Doctoral Prize 2020 in the field of health.

Link to page: Engineering T cells for cancer therapy efficiently and safely
Latest News

Engineering T cells for cancer therapy efficiently and safely

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells. At the National Center of Tumor Diseases (NCT) Heidelberg, therapeutic T cells produced with the novel vector were able to target and fight cancer more efficiently than conventionally produced cellular therapies.

Link to page: A new bridge connects research and industry
beLAB 2122

A new bridge connects research and industry

Drug discovery alliance and development partnership company Evotec launches „beLAB2122", translating academic innovation from leading German Life Science Region in collaboration with Bristol Myers Squibb. The German Cancer Research Center (DKFZ) is one of the academic partners of the cooperation project.

Link to page: Which patients benefit from immunotherapy?
Liver cancer:

Which patients benefit from immunotherapy?

Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an experimental model, this type of immunotherapy actually promoted the development of liver cancer, as now reported in the journal Nature.

Cancer in the EU

to top
powered by webEdition CMS